BioCardia (NASDAQ:BCDA) Posts Earnings Results

BioCardia (NASDAQ:BCDA) posted its quarterly earnings data on Wednesday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.62, Zacks reports. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. During the same quarter last year, the business earned ($8.19) EPS.

BioCardia Trading Up 5.1 %

Shares of BCDA opened at $2.68 on Friday. BioCardia has a twelve month low of $1.63 and a twelve month high of $6.30. The firm has a market capitalization of $12.29 million, a P/E ratio of -0.64 and a beta of 1.28. The stock’s fifty day simple moving average is $2.45 and its 200 day simple moving average is $2.41.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on BCDA shares. Alliance Global Partners raised BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of BioCardia in a research report on Wednesday, December 18th.

Insider Buying and Selling at BioCardia

In other BioCardia news, Director Simon H. Stertzer bought 22,753 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were acquired at an average price of $2.30 per share, with a total value of $52,331.90. Following the purchase, the director now owns 40,602 shares in the company, valued at approximately $93,384.60. The trade was a 127.47 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders bought 25,353 shares of company stock valued at $58,525. Company insiders own 20.00% of the company’s stock.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.